Arthur Feldman

failure patients. He has held significant leadership positions in academic medicine including serving as Chief of Cardiology at the University of Pittsburgh, Chair of the Department of Medicine at Thomas Jefferson University, and Executive Dean of the School of Medicine at Temple University. He served as the chair or co‑chair of PEECH, EMOTE, COMPANION, ESPRIT, Vesnarinone (Phases 1, 2, and 3), WEAR‑iT, and a CMS‑funded study of telemedicine. He also served on the steering committees that oversaw REMODEL, RENAISSANCE, ESSENTIAL, IMAC, GRAFH‑1, GRAFH‑2, and STICH, as the Chair of the Endpoint Committee for VEST, and Chair of the Data and Safety Monitor Committee of PROFILE. Feldman co‑founded three biotechnology companies prior to Renovacor. CPEC, Inc. was a spin‑out of Stanford, Utah and Johns Hopkins, which developed the drug bucindolol, a drug now under evaluation by ARCA Biopharma for the treatment of atrial fibrillation in patients with the β1389 arginine homozygous genotype. Feldman’s second company, C2R, was a boutique clinical research organization focused on cardiovascular clinical trials. Finally, Cardiokine was founded with intellectual property developed by Feldman at the University of Pittsburgh and the in‑license of a lead compound from Wyeth Pharmaceuticals. Feldman raised $30M in a Series A round, $50M in a Series B round, and $50M from a business development deal with Biogen‑Idec. Feldman is the founder of Renovacor and will serve as a Director on the Board of Directors.